P. Combemale

Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial

Michael R. Migden, Alexander Guminski, Ralf Gutzmer et al. · The Lancet Oncology · 2015 · 419 citations

Surgical Oncology, Medicine, Metronomic Therapy +6

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

Alexander Eggermont, Christian U. Blank, Mario Mandalà et al. · The Lancet Oncology · 2021 · 364 citations · Full text

Surgical Oncology, Medicine, Melanoma +8

Translocation, t(17;22)(q22;q13), in dermatofibrosarcoma protuberans: a new tumor-associated chromosome rearrangement

Florence Pédeutour, Marie‐Pierre Simon, Fabiola Minoletti et al. · Cytogenetic and Genome Research · 1996 · 194 citations

Long‐term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30‐month analysis of the randomized phase 2 BOLT study

John T. Lear, Michael R. Migden, Karl D. Lewis et al. · Journal of the European Academy of Dermatology and Venereology · 2017 · 189 citations · Full text

Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase II randomized, double‐blind BOLT study

Reinhard Dummer, Alexander D. Guminksi, Ralf Gutzmer et al. · British Journal of Dermatology · 2019 · 183 citations · Full text